Cargando…
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
BACKGROUND: Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is characterized by the growth of different types of tumours. Haemangioblastomas in the central nervous system (CNS) and retina, renal carcinoma and pheochromocytomas are the most common tumo...
Autores principales: | Albiñana, Virginia, Escribano, Rosa María Jiménez, Soler, Isabel, Padial, Luis Rodríguez, Recio-Poveda, Lucia, Villar Gómez de las Heras, Karina, Botella, Luisa María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492903/ https://www.ncbi.nlm.nih.gov/pubmed/28662711 http://dx.doi.org/10.1186/s13023-017-0664-7 |
Ejemplares similares
-
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
por: González-Rodríguez, Beatriz, et al.
Publicado: (2019) -
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
por: Albiñana, Virginia, et al.
Publicado: (2015) -
The Endothelial Landscape and Its Role in Von Hippel–Lindau Disease
por: de Rojas-P, Isabel, et al.
Publicado: (2021) -
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
por: Cuesta, A. M., et al.
Publicado: (2019) -
Retinal haemangioblastomas in von Hippel–Lindau germline mutation carriers: progression, complications and treatment outcome
por: Hajjaj, Anass, et al.
Publicado: (2020)